Health Canada has approved an amendment to Optimi Health’s (OTCQX: OPTHF) dealer's license, effectively allowing the company to supply MDMA and psilocybin drugs to the country’s Special Access Program (SAP.) 

Since Jan. 2022 physicians have been allowed to request lawful access to restricted substances for their patients through the program, following an amendment to the Controlled Drugs and Substances Act federal regulations.

CEO Bill Ciprick says Optimi’s “consistent dedication” over recent months has strengthened its capabilities in GMP-compliant psychedelics production. 

See Also: Sacred Medicine Meets Wall Street: Legal Peyote Company Will Trade On Canadian Market

"The hard work during this time ensures that …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.